News

BioMarin established a marketing and distribution agreement with AnGes in December 2006, through which AnGes obtained exclusive rights to market Naglazyme in the Japanese market. Naglazyme was already

Mircera is the only FDA-approved erythropoiesis-stimulating agent (ESA) to provide correction of anemia with once-every-two-week dosing. Mircera is also the only FDA-approved ESA to maintain stable hemoglobin levels

The products will be based on a combination of intellectual property (IP) from Hadasit and Anadis. Hadasit will contribute user specific methods for the treatment of immune mediated

The cash purchase price includes the purchase of certain real estate assets utilized by the business which will be sold simultaneously with the closing of the transaction to

Researchers at the University of Leuven and ThromboGenics have developed a novel therapeutic approach, showing that the inhibition of VPAC could stimulate the production of platelets. ThromboGenics has

The underwriters have options to purchase approximately 279,000 additional shares of preferred stock and approximately 8.025 million shares of common stock, in each case to cover over-allotments, if

Under the terms of the settlement, Schering-Plough will receive a license to OraSure’s patents in the US over-the-counter (OTC) market and OraSure will receive payments of past and

The goal of the joint venture, which the companies will be finalizing over the next several months, is to utilize the Andara oscillating field stimulator (OFS) technology to

The independent study (NCIC CTG CO.17) involved 572 patients and demonstrated that treating patients with Erbitux as a monotherapy plus best supportive care (BSC) significantly increased overall survival